Evidence map›Paper›PMID 39518607›Full record

ArticleJournal of clinical medicine2024

Acute Myeloid Leukemia as a Trigger for Hemolytic-Uremic Syndrome.

Jonas El Bachouti, Anna Domínguez-Guasch, Yolanda Arce, Guadalupe Oñate, Helena Marco, Montserrat Diaz, Lluís Guirado, Roser Torra, Xoana Barros

Abstract readCase Reports
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jonas El BachoutiDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0009-0009-2211-6390
Anna Domínguez-GuaschDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0000-0002-9322-7479
Yolanda ArceDepartment of Pathology, Fundació Puigvert, 08025 Barcelona, Spain.
Guadalupe OñateDepartment of Hematology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.ORCID 0000-0003-2180-2371
Helena MarcoDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0000-0003-3454-5837
Montserrat DiazDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0000-0001-5172-3370
Lluís GuiradoDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0000-0001-5119-3912
Roser TorraDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.
Xoana BarrosDepartment of Nephrology, Fundació Puigvert, 08025 Barcelona, Spain.ORCID 0000-0001-9690-9769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) has not been identified as a cause of secondary hemolytic-uremic syndrome (HUS). This case report describes a woman who developed severe HUS at the time of AML diagnosis and responded favorably to initial treatment with eculizumab, which stabilized her condition and allowed for treatment of the AML. After one year, with stable renal function and genetic studies reported as normal, eculizumab was successfully discontinued. The prompt use of eculizumab was critical to the patient's survival and improvement in renal function, highlighting the efficacy of early eculizumab treatment in secondary HUS.

Indexed as

acute myeloid leukemiaeculizumabhemolytic uremic syndrome

Identifiers

PMID39518607
PMCPMC11547072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.